New drug cocktail aims to stall prostate cancer in men with PTEN mutation

NCT ID NCT04493853

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a PTEN gene deficiency. Participants receive either the drug combo or a placebo, and the main goal is to see how long until the cancer progresses or death occurs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,012 people

The number who actually took part.

Started

Jul 2020

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Asymptomatic or mildly symptomatic, histologically-confirmed de novo hormone-sensitive prostate adenocarcinoma without small-cell tumours diagnosed within 180 days of randomisation * Consent to provide a FFPE tissue block (preferred) or slides. Tissue from bone metastases is not acceptable * A valid PTEN IHC result indicating PTEN deficiency (centralized testing) * Metastatic disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion accurately assessed at baseline and suitable for repeated assessment with CT and/or MRI. PSMA PET identification only will not be eligible * Candidate for abiraterone and steroid therapy * Ongoing ADT with GnRH analogue, or LHRH agonists or antagonist, or bilateral orchiectomy (regardless of method) is from 0 days to a max. of 93 days prior to randomisation * Eastern Cooperative Oncology Group (ECOG)/WHO performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks * Able and willing to swallow and retain oral medication * 7-day Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory(BFI) questionnaires and the analgesic diary during screening completed. Participants must complete a minimum of 4 successful assessments within a 7-day period prior to randomisation. * Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm * Capable of giving signed informed consent * Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples Exclusion Criteria: * Prior radical prostatectomy or definitive radiotherapy with therapeutic intent for prostate cancer. Palliative radiotherapy is allowed providing any wide field radiation therapy is completed more than 4 weeks before the start of study treatment * Major surgery (excluding placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, or internal stents) within 4 weeks of the start of study treatment * Brain metastases, or spinal cord compression (unless spinal cord compression is asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment) * Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease * Any of the following cardiac criteria: i. Mean resting corrected QT interval (QTc) \> 470 msec obtained from triplicate ECGs ii. History of QT prolongation associated with other medications that required discontinuation of that medication. iii. Family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives. iv. Medical history significant for arrhythmia which is symptomatic or requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. v. Any clinically important abnormalities in conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block) vi. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, or any concomitant medication known to significantly prolong the QT interval vii. Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft, angioplasty, myocardial infarction, angina pectoris. viii. Congestive heart failure NYHA Grade ≥ 2 ix. Symptomatic hypotension - systolic blood pressure (SBP) \<90 mmHg and/or diastolic blood pressure (DBP) \<50 mmHg x. Uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 95 mmHg). * Clinically significant abnormalities of glucose metabolism as defined by any of the following: i. Patients with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment ii. HbA1c ≥8.0% (63.9 mmol/mol) * Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: i. Absolute neutrophil count \< 1.5x 10\^9/L ii. Platelet count \< 100x 10\^9/L iii. Haemoglobin \< 9 g/dL (\< 5.59 mmol/L) iv. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2.5x upper limit of normal (ULN) if no demonstrable liver metastases or \> 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total bilirubin \> 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. Creatinine clearance \< 50 mL/min (measured or calculated by Cockcroft and Gault equation) * As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or known active infection including hepatitis B, hepatitis C, and HIV * unevaluable for both bone and soft tissue progression as defined by meeting both of the following criteria: i. a "superscan" of bone scan, and ii. no soft tissue lesion that can be assessed by RECIST criteria * Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent * Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent * Previous allogeneic bone marrow transplant or solid organ transplant * History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease. * Treatment with any of the following: i. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment ii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iii. Any other chemotherapy, immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents within 3 weeks of the first dose of study treatment. A longer washout may be required for drugs with a long half-life (eg, biologics) iv. Strong inhibitors or strong inducers of CYP3A4 within 2 weeks before the start of study treatment (3 weeks for St John's wort). Note that adequate washout or dose reduction may be required for some CYP3A substrates prior to initiating Capivasertib dosing. * Drugs known to significantly prolong the QT interval and associated with Torsades de Pointes within 5 half-lives of the first dose of study treatment * Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives, whichever is longer. * History of hypersensitivity to active or inactive excipients of capivasertib, abiraterone, or drugs with a similar chemical structure or class. * Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). * Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. * Any restriction or contraindication based on the local prescribing information that would prohibit the use of abiraterone.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hormone sensitive prostate cancer

Contacts and locations

Locations

Research Site

Tucson, Arizona, 85723, United States
Research Site

Tucson, Arizona, 85741, United States
Research Site

La Jolla, California, 92037, United States
Research Site

Orange, California, 92868, United States
Research Site

San Diego, California, 92123, United States
Research Site

Denver, Colorado, 80211, United States
Research Site

Lakewood, Colorado, 80215, United States
Research Site

Norwich, Connecticut, 06360, United States
Research Site

Fort Myers, Florida, 33901-8101, United States
Research Site

West Palm Beach, Florida, 33401, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Geneva, Illinois, 60134, United States
Research Site

Lisle, Illinois, 60532, United States
Research Site

Baltimore, Maryland, 21201, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Grand Rapids, Michigan, 49503, United States
Research Site

Troy, Michigan, 48084, United States
Research Site

Syracuse, New York, 13210, United States
Research Site

The Bronx, New York, 10461, United States
Research Site

Asheville, North Carolina, 28805, United States
Research Site

Durham, North Carolina, 27710, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Lancaster, Pennsylvania, 17601, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Pittsburgh, Pennsylvania, 15232, United States
Research Site

Charleston, South Carolina, 29401, United States
Research Site

Myrtle Beach, South Carolina, 29572, United States
Research Site

Chattanooga, Tennessee, 37404, United States
Research Site

Houston, Texas, 77090, United States
Research Site

Norfolk, Virginia, 23502, United States
Research Site

Roanoke, Virginia, 24014, United States
Research Site

Seattle, Washington, 98104, United States
Research Site

Madison, Wisconsin, 53792, United States
Research Site

Berazategui, B1884BBF, Argentina
Research Site

Buenos Aires, 1426, Argentina
Research Site

CABA, 1425, Argentina
Research Site

CABA, C1012AAR, Argentina
Research Site

Ciudad de Buenos Aires, C1120AAT, Argentina
Research Site

Ciudad de Buenos Aires, C1280AEB, Argentina
Research Site

La Plata, 1900, Argentina
Research Site

Mendoza, 5500, Argentina
Research Site

Rosario, S2000DEJ, Argentina
Research Site

San Salvador de Jujuy, 4600, Argentina
Research Site

Birtinya, 4575, Australia
Research Site

Darlinghurst, 2010, Australia
Research Site

Kingswood, 2747, Australia
Research Site

Orange, 2800, Australia
Research Site

South Brisbane, 4101, Australia
Research Site

Graz, 8036, Austria
Research Site

Linz, 4020, Austria
Research Site

Salzburg, 5020, Austria
Research Site

Anderlecht, 1070, Belgium
Research Site

Ghent, 9000, Belgium
Research Site

Kortrijk, 8500, Belgium
Research Site

Liège, 4000, Belgium
Research Site

Belém, 66073-005, Brazil
Research Site

Belo Horizonte, 30110-022, Brazil
Research Site

Florianópolis, 88020-210, Brazil
Research Site

Fortaleza, 60135-237, Brazil
Research Site

Jaú, 17210-120, Brazil
Research Site

Joinville, 89201-260, Brazil
Research Site

Porto Alegre, 90035-000, Brazil
Research Site

Porto Alegre, 90050-170, Brazil
Research Site

Porto Alegre, 90160-093, Brazil
Research Site

Ribeirão Preto, 14051-140, Brazil
Research Site

Rio de Janeiro, 20230-130, Brazil
Research Site

Santa Maria, 97015-450, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 01327-001, Brazil
Research Site

Três Lagoas, 79601-001, Brazil
Research Site

Pleven, 5804, Bulgaria
Research Site

Plovdiv, 4004, Bulgaria
Research Site

Plovdiv, 4109, Bulgaria
Research Site

Sofia, 1407, Bulgaria
Research Site

Sofia, 1527, Bulgaria
Research Site

Sofia, 1756, Bulgaria
Research Site

Sofia, 1797, Bulgaria
Research Site

Varna, 9000, Bulgaria
Research Site

Calgary, Alberta, T2N 5G2, Canada
Research Site

Edmonton, Alberta, T6G 1Z2, Canada
Research Site

Kelowna, British Columbia, V1Y 5L3, Canada
Research Site

Vancouver, British Columbia, V5Z 1H7, Canada
Research Site

Brampton, Ontario, L6R 3J7, Canada
Research Site

Oshawa, Ontario, L1G 2B9, Canada
Research Site

Toronto, Ontario, M4N 3M5, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Montreal, H3T 1E2, Canada
Research Site

Santiago, 7500653, Chile
Research Site

Santiago, 7500787, Chile
Research Site

Santiago, 8420383, Chile
Research Site

Temuco, 4781156, Chile
Research Site

Viña del Mar, 2540488, Chile
Research Site

Beijing, 100034, China
Research Site

Beijing, 100036, China
Research Site

Beijing, 100050, China
Research Site

Beijing, CN-100730, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410003, China
Research Site

Changsha, 410008, China
Research Site

Chengdu, 610000, China
Research Site

Chengdu, 610072, China
Research Site

Chongqing, 400030, China
Research Site

Chongqing, 400038, China
Research Site

Fuzhou, 350001, China
Research Site

Fuzhou, 350005, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510180, China
Research Site

Guangzhou, 510515, China
Research Site

Guiyang, 550002, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310014, China
Research Site

Hangzhou, 310052, China
Research Site

Kunming, 650118, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 2100008, China
Research Site

Nanjing, 210009, China
Research Site

Nantong, 226361, China
Research Site

Ningbo, 315000, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200080, China
Research Site

Shanghai, 200127, China
Research Site

Shengyang, 110004, China
Research Site

Tianjin, 300211, China
Research Site

Wenzhou, CN-325000, China
Research Site

Wuhan, 430030, China
Research Site

Xi'an, 710061, China
Research Site

Yantai, 264000, China
Research Site

Zhengzhou, 450000, China
Research Site

Zhengzhou, 450008, China
Research Site

Brno, 656 91, Czechia
Research Site

Hořovice, 268 31, Czechia
Research Site

Hradec Králové, 500 05, Czechia
Research Site

Prague, 100 34, Czechia
Research Site

Prague, 120 00, Czechia
Research Site

Prague, 180 81, Czechia
Research Site

Besançon, 25030, France
Research Site

Bordeaux, 33076, France
Research Site

Marseille, 13273, France
Research Site

Montpellier, 34298, France
Research Site

Nice, 06100, France
Research Site

Paris, 75674, France
Research Site

Pierre-Bénite, 69495, France
Research Site

Quimper, 29107, France
Research Site

Rennes, 35033, France
Research Site

Strasbourg, 67098, France
Research Site

Suresnes, 92151, France
Research Site

Villejuif, 94805, France
Research Site

Berlin, 10117, Germany
Research Site

Duisburg, 47169, Germany
Research Site

Hamburg, 20246, Germany
Research Site

Herne, 44625, Germany
Research Site

Mettmann, 40822, Germany
Research Site

Münster, 48149, Germany
Research Site

Nuremberg, 90419, Germany
Research Site

Nürtingen, 72622, Germany
Research Site

Wesel, 46483, Germany
Research Site

Hong Kong, 00000, Hong Kong
Research Site

Hong Kong, Hong Kong
Research Site

Lai Chi Kok, Hong Kong
Research Site

Ahmedabad, 380060, India
Research Site

Bangalore, 560022, India
Research Site

Bangalore, 560027, India
Research Site

Delhi, 110085, India
Research Site

Faridabad, 121001, India
Research Site

Kanpur, 208005, India
Research Site

Kolkata, 700160, India
Research Site

Madurai, 625107, India
Research Site

Manipal, 576104, India
Research Site

Meerut, 250001, India
Research Site

Mohali, 160055, India
Research Site

Nagpur, 440001, India
Research Site

New Delhi, 110005, India
Research Site

New Delhi, 11029, India
Research Site

Thiruvananthapuram, 695 011, India
Research Site

Varanasi, 221005, India
Research Site

Haifa, 3109601, Israel
Research Site

Jerusalem, 91120, Israel
Research Site

Kfar Saba, 95847, Israel
Research Site

Petah Tikva, 4941492, Israel
Research Site

Ramat Gan, 52621, Israel
Research Site

Ẕerifin, 70300, Israel
Research Site

Bunkyō City, 113-8431, Japan
Research Site

Chiba, 260-8677, Japan
Research Site

Chūōku, 260-8717, Japan
Research Site

Fukuoka, 812-8582, Japan
Research Site

Hamamatsu, 431-3192, Japan
Research Site

Hirakata-shi, 573-1191, Japan
Research Site

Hirosaki-shi, 036-8563, Japan
Research Site

Isehara-shi, 259-1193, Japan
Research Site

Kanazawa, 920-8641, Japan
Research Site

Kashihara-shi, 634-8522, Japan
Research Site

Kawagoe-shi, 350-8550, Japan
Research Site

Kisarazu-shi, 292-8535, Japan
Research Site

Kita-gun, 761-0793, Japan
Research Site

Kobe, 650-0047, Japan
Research Site

Kumamoto, 860-0008, Japan
Research Site

Kyoto, 606-8507, Japan
Research Site

Miyazaki, 889-1692, Japan
Research Site

Morioka, 028-3695, Japan
Research Site

Nagano, 381-8551, Japan
Research Site

Nagasaki, 852-8501, Japan
Research Site

Nagoya, 466-8560, Japan
Research Site

Nagoya, 466-8650, Japan
Research Site

Natori-shi, 981-1293, Japan
Research Site

Osaka, 541-8567, Japan
Research Site

Osakasayama-shi, 589-8511, Japan
Research Site

Ota Shi, 373-8550, Japan
Research Site

Sagamihara-shi, 252-0375, Japan
Research Site

Sapporo, 060-8648, Japan
Research Site

Shinjuku-ku, 160-8582, Japan
Research Site

Toon-shi, 791-0295, Japan
Research Site

Tsu, 514-8507, Japan
Research Site

Ube-shi, 755-8505, Japan
Research Site

Yokohama, 232-0024, Japan
Research Site

Yokosuka-shi, 238-8558, Japan
Research Site

Yufu-shi, 879-5593, Japan
Research Site

Culiacán, 80040, Mexico
Research Site

Culiacán, 80230, Mexico
Research Site

Guadalajara, 44680, Mexico
Research Site

Mexico City, 0 3100, Mexico
Research Site

Monterrey, 64460, Mexico
Research Site

Monterrey, 64710, Mexico
Research Site

Amsterdam, 1066 CX, Netherlands
Research Site

Hilversum, 1212 VG, Netherlands
Research Site

Roosendaal, 4708 AE, Netherlands
Research Site

The Hague, 2545 AA, Netherlands
Research Site

Tilburg, 5042AD, Netherlands
Research Site

Utrecht, 3543 AZ, Netherlands
Research Site

Callao, CALLAO 02, Peru
Research Site

Lima, 0051, Peru
Research Site

Lima, LIMA 29, Peru
Research Site

Lima, LIMA 31, Peru
Research Site

Lima, Lima 32, Peru
Research Site

Lima, LIMA 34, Peru
Research Site

San Isidro, 27, Peru
Research Site

Baguio City, 2600, Philippines
Research Site

Cebu City, 6000, Philippines
Research Site

Davao City, 8000, Philippines
Research Site

Iloilo City, 5000, Philippines
Research Site

Quezon City, 1101, Philippines
Research Site

Quezon City, 1112, Philippines
Research Site

San Juan City, 1500, Philippines
Research Site

Bydgoszcz, 85-796, Poland
Research Site

Gdansk, 80-214, Poland
Research Site

Koszalin, 75-581, Poland
Research Site

Lodz, 90-242, Poland
Research Site

Olsztyn, 10-228, Poland
Research Site

Poznan, 61-731, Poland
Research Site

Rzeszów, 35-055, Poland
Research Site

Torun, 87-100, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Warsaw, 04-073, Poland
Research Site

Moscow, 105077, Russia
Research Site

Moscow, 117997, Russia
Research Site

Moscow, 121205, Russia
Research Site

Novisibirsk, 630082, Russia
Research Site

Novosibirsk, 630007, Russia
Research Site

Saint Petersburg, 190103, Russia
Research Site

Saint Petersburg, 191014, Russia
Research Site

Yaroslavl, 150054, Russia
Research Site

Bratislava, 81102, Slovakia
Research Site

Bratislava, 851 05, Slovakia
Research Site

Martin, 036 59, Slovakia
Research Site

Nitra, 49401, Slovakia
Research Site

Prešov, 08001, Slovakia
Research Site

Šaľa, 92701, Slovakia
Research Site

Trenčín, 911 01, Slovakia
Research Site

Cape Town, 7570, South Africa
Research Site

Johannesburg, 2013, South Africa
Research Site

Johannesburg, 2193, South Africa
Research Site

Parow, 7505, South Africa
Research Site

Port Elizabeth, 6045, South Africa
Research Site

Pretoria, 0084, South Africa
Research Site

Daegu, 41404, South Korea
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Badalona (Barcelona), 08916, Spain
Research Site

Barcelona, 08041, Spain
Research Site

Las Palmas de Gran Canaria, 35016, Spain
Research Site

Madrid, 28007, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28040, Spain
Research Site

Madrid, 28041, Spain
Research Site

Oviedo, 33011, Spain
Research Site

Santander, 39008, Spain
Research Site

Seville, 41009, Spain
Research Site

Kaohsiung City, 807, Taiwan
Research Site

Kaohsiung City, 81362, Taiwan
Research Site

Taichung, 404, Taiwan
Research Site

Taichung, 43503, Taiwan
Research Site

Tainan, 710, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taipei, 11490, Taiwan
Research Site

Taoyuan City, 333, Taiwan
Research Site

Bangkok, 10210, Thailand
Research Site

Bangkok, 10400, Thailand
Research Site

Bangkok, 10700, Thailand
Research Site

Chiang Mai, 50200, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Lampang, 52000, Thailand
Research Site

Muang, 22000, Thailand
Research Site

Ankara, 06010, Turkey (Türkiye)
Research Site

Ankara, Turkey (Türkiye)
Research Site

Antalya, 07059, Turkey (Türkiye)
Research Site

Eskişehir, 26040, Turkey (Türkiye)
Research Site

Istanbul, 34098, Turkey (Türkiye)
Research Site

Izmir, 35100, Turkey (Türkiye)
Research Site

Izmir, 35575, Turkey (Türkiye)
Research Site

Kayseri, 38039, Turkey (Türkiye)
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Guildford, GU2 7XX, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Plymouth, PL6 8DH, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom
Research Site

Whitchurch, CF14 2TL, United Kingdom
Research Site

Hanoi, 100000, Vietnam
Research Site

Hà Nội, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.